Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BioTTT 001

Next Previous
X
Search
Drug Profile

BioTTT 001

Alternative Names: Ad-TD-nsIL12; BioTTT-001; Recombinant human nsIL12 oncolytic adenovirus injection

Latest Information Update: 08 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Bio-Targeting Therapeutics Technology
  • Developer Beijing Bio-Targeting Therapeutics Technology; Beijing Sanbo Brain Hospital
  • Class Antineoplastics; Gene therapies; Immunotherapies; Interleukins; Oncolytic viruses; Recombinant proteins
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma
  • Preclinical Solid tumours

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from the phase I trial in Glioblastoma presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 04 Mar 2024 China Medical University and Beijing Bio-Targeting Therapeutics Technology initiated a phase I trial for Colorectal cancer (Combination therapy, Second-line therapy or greater, Monotherapy, Metastatic disease) in April 2024 (Intraperitoneal) (NCT06283134)
  • 29 Feb 2024 China Medical University, China in collaboration with Beijing Bio-Targeting Therapeutics Technology plans a phase II trial for Gastric cancer (Metastatic disease, Combination therapy, Monotherapy) (Intraperitoneal, infusion) in April 2024 (NCT06283121)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top